RxDoctor Payments Data

Joseph Creevy, MD

Internal Medicine · Sarasota, FLNPI 1710959408

Payments from drug & device makers

$635in general payments, 2019–2025

Across 31 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$123
  • Exact Sciences$119
  • Novartis$86
  • Novo Nordisk$79
  • Astellas Pharma US Inc$61
  • GSK$56
  • plus $111 from 5 others

What the payments were for

  • Food & beverage$635100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$635 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$504,926
Medicare patients
1,103
Services billed
9,813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban169$240,714
XareltoRivaroxaban81$104,059
OzempicSemaglutide60$96,867
TrulicityDulaglutide53$91,499
MounjaroTirzepatide73$91,247
JardianceEmpagliflozin59$80,841
JanuviaSitagliptin Phosphate38$60,819
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$43,540
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr35$30,902
Tresiba Flextouch U-100Insulin Degludec44$30,060
MyrbetriqMirabegron22$20,928
WegovySemaglutide16$20,493
JanumetSitagliptin Phos/Metformin Hcl13$20,409
RybelsusSemaglutide12$17,580
Valsartan437$10,753

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$42$240,714169 claims
Lilly USA, LLCTrulicity, Mounjaro$123$182,746126 claims
Novo NordiskOzempic, Wegovy, Rybelsus$79$134,94088 claims
MerckJanuvia, Janumet$16$81,22851 claims
GSKTrelegy Ellipta, Anoro Ellipta$56$74,44275 claims
Astellas Pharma US IncMyrbetriq$61$20,92822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →